



## Financial Tear Sheet

### Corporate Profile

Navidea Biopharmaceuticals is a commercial stage biotechnology company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing the precision-targeted Manocept™ platform to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea's first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company's pipeline through global partnering and commercialization efforts. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

#### Primary IR Contact

Tom Baker

E-mail: [ir@navidea.com](mailto:ir@navidea.com)

### Stock Performance

#### NAVB (Common Stock)

Exchange	NYSE Amex (US Dollar)
Price	\$0.44
Change (%)	▼ 0.02 (4.35%)
Volume	343,321
52 Week Low	\$0.26
Market Cap	\$71,720,964
Rolling EPS	0.45
PE Ratio	0.985556

Shares Outstanding 161,898,338

Data as of 05/25/17 4:02 p.m. ET

■ NAVDEA BIOPHARMACEUTICALS INC  
as of 5/24/2017



EDGAR Online

### Recent Press Releases

Date	Title
05/09/17	<a href="#">Navidea Biopharmaceuticals Reports First Quarter 2017 Financial Results</a>
04/25/17	<a href="#">Navidea Biopharmaceuticals Invited to Present Data at Two Major Upcoming Conferences</a>
03/29/17	<a href="#">Navidea Provides Corporate Update and Reports Full Year 2016 Results</a>
03/03/17	<a href="#">Navidea Completes Sale of North American Rights of Lymphoseek® to Cardinal Health</a>

### SEC Filings

Filing Date	Form
05/24/17	<a href="#">DEF 14A</a>
05/23/17	<a href="#">4</a>
05/19/17	<a href="#">4</a>
05/16/17	<a href="#">4</a>